相关实验视频
Updated: May 15, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
通过METTL3-介导的m6A修改PAK6通过激活MAPK14驱动子宫癌的进展
Zhi-Man Zhu1, Fu-Chun Huo1, Ce Shi2
1Department of Pathology, Xuzhou Medical University, 209 Tong-shan Road, Xuzhou 221004, Jiangsu, China.
N6-甲基氨酸 (m6A) 通过通过METTL3.3.稳定PAK6mRNA来调节子宫癌 (CC). 这种METTL3/PAK6通路促进CC细胞的增殖,迁移和入侵,提供潜在的治疗点.
科学领域:
- 史诗转录组学 史诗转录组学
- 分子瘤学分子瘤学
- 生物化学 生化学
背景情况:
- N6-甲基氨酸 (m6A) 是哺乳动物中最常见的mRNA修饰.
- m6A失调与子宫癌 (CC) 病原发生有关,但机制尚不清楚.
研究的目的:
- 阐明m6A修饰及其相关蛋白在CC进展中的作用.
- 确定关键的分子参与者和驱动CC生长和转移的途径.
主要方法:
- 确定了DDX5作为CC细胞中的METTL3结合伙伴.
- 使用m6A阅读器IGF2BP1.1研究了PAK6mRNA的METTL3介导的m6A修饰.
- 在CC细胞和体内模型中进行了功能增益和丧失研究.
- 分析了METTL3和PAK6表达相关性的临床CC标本.
主要成果:
- DDX5与METTL3相互作用,调节CC中的全球m6A水平.
- 通过IGF2BP1,METTL3稳定了PAK6mRNA,增强了CC细胞的增殖,迁移和入侵.
- 在Ser56中PAK6酸化MAPK14,促进CC的进展.
- 通过对PAK6.6进行上调,METTL3促进了CC的生长和转移.
- 临床CC样本显示METTL3和PAK6表达之间的正相关性.
结论:
- METTL3/PAK6轴是宫癌进展的关键驱动因素.
- 这一途径调节了CC细胞的增殖,迁移,入侵,生长和转移.
- METTL3和PAK6是宫癌治疗的潜在治疗点.
更多相关视频
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
相关概念视频
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
PI3K/mTOR/AKT Signaling Pathway